stockrow
Saturday 7 November 2026
Export SABS’s income statement to Excel — free account
SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023.
- Revenue
- −91.0%
- EPS
- +74.3%
- Free cash flow
- −59.8%
- Total debt
- −5.01%
Quarter to June 2026, against a year earlier
3.00
0.06
+2.04%
Follow SABS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 55 | 61 | 24 | 2 | 1 | — | 2 | (60.7%) | — | 0 | 8 | +13,370.4% | |
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | — | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | 20 | (17) | (19) | (42) | (34) | 13 | (13) | (8.0%) | ||||||
| EBT margin, % | — | — | — | — | 36.42 | (28.16) | (78.29) | (1,884.49) | (2,579.05) | 0.00 | 0.00 | (36.4) pt | ||||||
| Net income | — | 0 | — | — | 20 | (17) | (19) | (42) | (34) | 13 | (13) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 21.75 | 22.27 | 5.49 | 0.41 | 0.14 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | 7.92 | (6.30) | (4.30) | (7.64) | (3.68) | 0.22 | (0.19) | (51.2%) | ||||||
| Cash flow | — | — | — | — | 3.94 | 0.73 | (5.39) | (4.55) | (3.70) | (2.32) | (0.68) | n/m | ||||||
| Capex | — | — | — | — | (5.01) | (4.00) | (0.48) | (0.03) | (0.04) | (0.05) | (0.04) | (60.5%) | ||||||
| Free cash flow | — | — | — | — | (1.07) | (3.28) | (5.87) | (4.58) | (3.74) | (2.37) | (0.72) | +17.2% | ||||||
| Book value | — | — | — | — | 15.36 | 14.10 | 7.14 | 10.38 | 2.80 | 7.84 | 2.69 | (12.6%) | ||||||
| Shares, m | — | — | — | — | 3 | 3 | 4 | 6 | 9 | 19 | 41 | +50.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 3.51 | 1.18 | 17.26 | 21.57 | — | 147.02 | 8.7 | ||||||
| P/B | — | — | — | — | 93,838.02 | 5.54 | 0.91 | 0.67 | 1.35 | — | 1.11 | 18,769.3 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 2.92 | 0.73 | (6.47) | 10.83 | — | 85.82 | 1.6 | ||||||
| EV/FCF | — | — | — | — | 0.00 | (19.84) | (0.68) | 0.57 | (0.51) | — | (2.43) | (4.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 10 | 2 | (23) | (25) | (34) | (45) | (54) | n/m | |||||
| Capex | — | — | — | — | (13) | (11) | (2) | 0 | 0 | (1) | (3) | (40.7%) | ||||||
| Free cash flow | — | — | — | — | (3) | (9) | (26) | (25) | (35) | (46) | (57) | +75.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 23 | 24 | 7 | 48 | 16 | 90 | 96 | +31.0% | |||||
| Net debt | — | — | — | — | (9) | (36) | (11) | (53) | (17) | (93) | (100) | +61.5% | ||||||
| Shareholders’ equity | — | — | — | — | 39 | 39 | 31 | 57 | 26 | 151 | 215 | +31.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 71.17 | (24.91) | (28.39) | (62.58) | (53.23) | 3.93 | (28.97) | (67.2) pt | |||||
| ROIC | — | — | — | — | 42.13 | (302.49) | (89.55) | (573.17) | (316.08) | (52.73) | (38.97) | (94.9) pt | ||||||
| ROE | — | — | — | — | 51.88 | (44.21) | (53.85) | (95.51) | (81.92) | 4.80 | (34.27) | (47.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 139 | 56 | 57 | 63 | 86 | — | (11.3%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.44 | 0.43 | 0.04 | 0.02 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Dec 2024 · fundamentals updated 26 Oct 2026
SAB Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NAUT Nautilus Biotechnology, Inc. | $273.9M | — (loss-making) | — | — | n/m | −28.59% (below 0%: shrinking) | 89.74% | (7,152.56%) | Compare |
| IPSC Century Therapeutics, Inc. | $273.4M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +26.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| TTRX Turn Therapeutics Inc. | $273.0M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | Compare |
| VOGX Vogenx Inc | $270.8M | — | — | — | n/m | — | — | 0.00% | Compare |
| SABS SAB Biotherapeutics, Inc. | $267.5M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | |
| RCKT Rocket Pharmaceuticals, Inc. | $267.3M | — (loss-making) | — | — | n/m | +19.16% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ARCT Arcturus Therapeutics Holdings Inc. | $266.0M | — (loss-making) | — (loss-making) | +6.68% (above 0%: growing) | n/m | +59.86% (above 0%: growing) | 100.00% | (50.20%) | Compare |
| SPRY ARS Pharmaceuticals, Inc. | $263.5M | — (loss-making) | — (loss-making) | +16.03% (above 0%: growing) | n/m | +36.52% (above 0%: growing) | 0.00% | (90.62%) | Compare |
| QTTB Q32 Bio Inc. | $263.5M | 3.1× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $269.1M | — | — | +11.36% | — | +26.66% | 94.87% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
25.03% of the votes
Andrew Moin
23.84% of the votes
RA Capital Healthcare Fund, L.P.
9.99% of the votes
Perceptive Advisors LLC
6.81% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement